期刊文献+

盐酸羟考酮控释片直肠给药控制癌痛的临床观察 被引量:2

Clinical observation of oxycodone hydrochloride controlled-release tablets for moderate and severe cancer pain by rectal administration
下载PDF
导出
摘要 目的观察盐酸羟考酮控释片(奥施康定)直肠给药治疗晚期癌症患者中、重度疼痛的临床效果、不良反应及患者的生活质量的改善情况。方法对23例癌痛患者采取直肠给药的方式,观察治疗前后的镇痛效果、不良反应及生活质量评分。结果 23例中、重度癌痛患者治疗2周后完全缓解(CR)11例,部分缓解(PR)9例,显著有效率为87.0%,平均镇痛起效时间80min,平均镇痛时间11.7h,治疗前平均KPS评分(36.09±8.39),治疗后(61.30±10.14),生活质量较前明显改善。不良反应主要为便秘。结论对于不能口服给药的患者,盐酸羟考酮控释片直肠给药具有良好的镇痛效果,不良反应少,程度轻,并能明显提高患者的生活质量。 Objective To observe the clinical effects and the adverse effects of oxycodone hydrochloride controlled-release tablets(oxycontin) by rectal administration in the treatment of moderate and severe pain in patients with terminal cancer and to observe any improvement on living quality of the cancer patients.Methods 23 patients suffering from moderate and severe cancer pain were treated with oxycodone hydrochloride controlled-tablets by rectal administration.The analgesic effects,karnofsky performance status scales(KPS) and adverse effects were observed.Results Among all the 23patients suffering from moderate and server cancer pain,11 achieved CR,9 achieved PR,and effective rate was 87.0%.The mean onset time of analgesic effect was 80 min,and the mean duration of analgesic effect was 11.7 h.Additionally,the karnofsky mark after treatment which was 61.30±10.14 was higher than before which was 36.09±8.39.The quality of life was significantly improved after treatment.Main effect was constipation.Conclusion The oxycodon hydrochloride controlled-release tablets by rectal administration can effectively control cancer pain.The adverse effects are mild and slight,and the drug can significantly improve the living quality for patients with cancer pain.
出处 《西部医学》 2011年第10期1922-1923,1926,共3页 Medical Journal of West China
关键词 盐酸羟考酮控释片 癌痛 直肠给药 Oxycodone hydrochloride controlled-release tablets Cancer pain Rectal administration
  • 相关文献

参考文献5

二级参考文献14

  • 1刘华,王蔚,郑垂志,邢雪花.癌症三阶梯止痛563例分析[J].中国肿瘤临床,2004,31(23):1346-1348. 被引量:79
  • 2徐国柱,蔡志基.镇痛药临床评价方法研究[J].中国新药杂志,1995,4(4):20-22. 被引量:256
  • 3李小梅,刘端祺,李红英,王艳梅.恶性肿瘤患者临终前的阿片类药物止痛回顾[J].中国肿瘤临床,2005,32(23):1358-1360. 被引量:36
  • 4孙燕.内科肿瘤学[M].北京:人民卫生出版社,1999.88.
  • 5Mercadante S ,Fulfaro F. Wodcl Health Organization guidelines for cancer pain :a reappraisal [ J ]. Ann Oncol, 2005,16 ( Suppl 4) :iv132-iv135.
  • 6Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone[J]. Br J Clin Pharmacol,1996,42(6) :747-756.
  • 7Cpeter NW,Dwight M, Judith WW. Controlle-release oxycodone relieves ncuropathic pain: a randomized controlled trial in painful diabetic neuropathy[ J]. Pain,2003,105:71-78.
  • 8Ackerman S J, Mordin M. Patient-reported utilization patterns of system and oxycodone hydroehloride controlled-release among patients with chronic nonmalignant pain [ J ]. Manag Care pharm ,2003,9 ( 3 ) : 223-231.
  • 9Kapil R,Nolting A,Roy P,et al.Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen:two randomized,open-label,crossover studies in healthy adult volunteers[J].Clin Ther,2004,26(12):2015~2025
  • 10Arcuri E,Ginobbi P,Tirelli W,et al.Preliminary in vivo experimental evidence on intratumoral morphine uptake.Possible clinical implications in cancer pain and opioid pesponsiveness[J].J Pain Symptom Manage,2002,24(1):1~3

共引文献34

同被引文献30

  • 1王萍,刘勇,汪涛,程宝智.盐酸羟考酮控释片治疗中重度癌痛疗效观察[J].现代肿瘤医学,2008,16(11):1983-1985. 被引量:18
  • 2徐瀚峰,郑勤,张全安,王礼学,丁婕.盐酸羟考酮控释片不同给药方式治疗中重度癌性疼痛的疗效比较[J].实用癌症杂志,2010,25(5):533-534. 被引量:22
  • 3兰海涛,邓春美.多瑞吉治疗癌性疼痛68例临床观察[J].西部医学,2005,17(2):150-151. 被引量:14
  • 4李小梅,刘端祺,李红英,王艳梅.恶性肿瘤患者临终前的阿片类药物止痛回顾[J].中国肿瘤临床,2005,32(23):1358-1360. 被引量:36
  • 5黄蕾,吴海鹰,刘俊玲,胡晓晔,戴文清,段海波.羟考酮控释片(奥施康定)缓解癌痛及改善肺癌患者生活质量的观察[J].中国疼痛医学杂志,2007,13(2):88-91. 被引量:28
  • 6Portenoy RK, Bruns D, Shoemaker B,et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics [J]. Opioid Mang, 2010,6(2) :97-108.
  • 7Novotna S,Valentova K, Frieova J, et al. A Randomized, Place- bo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm)for breakthrough pain in opioid-trea ted patients with cancerl-J/OL]. Clinical therapeutics, 2014,36 (3) :357-367.
  • 8Taylor DR,Webster LR,Chun SY,et al. Impact of breakthrough pain on quality of life in patients with chronic, non-cancer pain: patient perceptions and effect of treatment with oral transmuco- sal fentanyl citrate (OTFC,ACTIQ) [J]. Pain Med,2007,8(3) : 281-288.
  • 9Ashburn MA, Slevin KA, Messina J, et al. The efficacy and safe- ty of fentanyl buccal tablet compared with immediate-release oxycodone for the t'nanagement of breakthrough pain in opioid- tolerant patients with chronic pain [J]. Anesth Analg, 2011,112 (3) :693-702.
  • 10Webster LR,Slevin KA,Narayana A,et al. Fentanyl buccal tab- let compared with immediate-release oxycodone for the manage- ment of breakthrough pain in opioid-tolerant patients with chro- nic cancer and non-cancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evalu- ate patient outcomes [J]. Pain Medicine, 2013, 14 ( 9 ) : 1332- 1345.

引证文献2

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部